Publications, Pharmaceutical

Using pharmacokinetics to confirm bioequivalence in fluticasone DPIs

Streamlining the complexities of confirming the bioequivalence of generic orally inhaled drug products by would be helpful in reducing the costs of widely used respiratory therapeutics.

This paper describes pharmacokinetic studies of three fluticasone propionate dry powder inhaler formulations with respect to their effectiveness in detecting differences in regional deposition. The formulations were chosen for their ability to deliver deposition in different areas of the lung while at the same time ensuring a comparable overall dose. Systemic pharmacokinetics were assessed in a randomized, double-blind, four-way, crossover study, with 24 healthy volunteers. The results support the use of pharmacokinetic studies to provide relevant data for the assessment of pulmonary performance via parameters such as regional deposition, available dose, and residence time.

Download Publication
6 Feb 2021

Learn more about Aptar Pharma Expertise
in Pulmonary Drug Delivery

Find Out More

This Might Also Be of Interest

14 Dec 2022

Building Digital Solutions To Meet The Unique Therapeutic Needs of Patients

Publications, Pharmaceutical, Device Innovations, Product Solutions, Innovation & Insights

Read More
25 Nov 2022

Analytical Services in the Development of MDIs and DPIs

Brochures, Pharmaceutical, Innovation & Insights, Product Solutions

Read More
16 Nov 2022

From pMDI Device to Therapeutic Effect

Webinars, Pharmaceutical, Sustainability, Device Innovations, Market Insights, Product Solutions

Read More
21 Oct 2022

Physiologically-based Pharmacokinetic Models (PBPK) for OINDPs

Publications, Pharmaceutical, Device Innovations, Market Insights, Product Solutions

Read More
1 2 3 15
Back To Top